Open Site Navigation

Who we are

Our proprietary technology is safe and effective

We are world's first company to introduce salt particle inhalation to the market 

Dry NaCl powder inhaler

BREATHOX® is a dry NaCl powder inhaler containing micronized NaCl inhalable size ; 1-10 μm

The worlds only...

BREATHOX® is the worlds only medical device that dispense a metered dose of NaCl particles into the upper and lower airways

Cleaning airways

BREATHOX ® promotes the cleaning of the airways and relieves respiratory tract irritation and mucus accumulation

Natural Self-care Product

BREATHOX® supports the growing trend of natural therapies and self-care treatment in the consumer healtcare market

Liita_logo_green.png

Improving life through better breathing

At LIITA Care, we are developing novel therapies that improve the lives of people suffering from respiratory diseases

Achievement

Life Is In The Air

We have developed a novel treatment platform, that enables respiratory self-care patients to adopt first line ‘standard of care’ outside of hospitals

We aspire...

to make the world a better place – to breathe

For chronic patients, such as:

  • COPD patients

  • Cystic Fibrosis patients

  • Asthma patients

For temporary patients, such as:

  • Common Cold patients

  • Covid-19 patients

  • Pollution victims

  • Smokers

Liita_logo_green.png

What We Do

Creating respiratory self-care solutions

We are focused on creating a respiratory self-care portfolio, based on our proprietary inhalation technology, for larger consumer healthcare players to bring to market

Products

  • Dry/Wet Salt

  • Nasal/Oral 

Indications

  • Antiviral

  • Anti-inflammatory

  • Pediatric

Latest News

Catch up on the latest news & updates here

05 September 2022 • Press Release

New Scientific Discovery Points Toward a Natural Solution for Mild to Moderate Covid-19 Patients

We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona.
 
“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form”
 
“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil).
 
 

02 September 2022 • Media Update

LIITA Research to be Presented at ERS Congress 2022

We are proud to announce that our latest scientific discovery was selected by the European Respiratory Society to be presented as Late-Breaking Abstract in the category ‘Best abstracts in COVID-19’ at the forthcoming ERS International Congress in Barcelona. 

 

“We see ERS’ acceptance as an endorsement of our research and the vast treatment potential that the result implies,” says CEO Martin A. Ohrt“ We hope that the publication of our discoveries in the anti-viral field will lead to more collaborations in which we can further uncover the therapeutic potential of the BREATHOX® treatment form” 

 

“Efficacy of Breathox® device inhalation on acute symptoms associated with COVID-19“ is presented by Investigation Leader Pr. Suzana Erico Tanni (UNESP, Brazil). 

 

Come join us Monday the 5th of September at 12.45 pm (Room 8L).

2022 • News Article

Stay tuned for more news

TBA

Browse All News

Latest News

Catch up on the latest news & updates here

Latest News

Catch up on the latest news & updates here